4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a building block and synthetic intermediate.1,2,3,4,5 It has been used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer compounds.1,2,3 It is also a synthetic intermediate in the synthesis of EGFR inhibitors, including erlotinib , with antiproliferative activity.4,5
1.Pandey, A., Volkots, D.L., Seroogy, J.M., et al.Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase familyJ. Med. Chem.45(17)3772-3793(2002) 2.Li, W.W., Wang, X.Y., Zheng, R.L., et al.Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivoJ. Med. Chem.55(8)3852-3866(2012) 3.Zhang, X., Su, M., Chen, Y., et al.The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitorsMolecules18(6)6491-6503(2013) 4.Liu, Z., Wang, L., Feng, M., et al.New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancersBioorg. Chem.77593-599(2018) 5.Knesl, P., RÖseling, D., and Jordis, U.Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: Tandutinib, erlotinib and gefitinibMolecules11(4)286-297(2006)